Report Overview
The Medical Affairs Outsourcing Market Size is expected to be worth around US$ 3.6 billion by 2033 from US$ 1.8 billion in 2023, growing at a CAGR of 7.2% during the forecast period 2024 to 2033.
Growing demand for efficient drug development processes and the need for enhanced communication between pharmaceutical companies and healthcare professionals are driving the expansion of the medical affairs outsourcing market. Companies increasingly outsource medical affairs functions such as regulatory support, medical writing, and clinical data management to streamline operations and reduce costs.
Medical affairs outsourcing plays a crucial role in facilitating the exchange of scientific information, managing key opinion leader (KOL) relationships, and ensuring compliance with evolving healthcare regulations. In March 2021, Hospital Alemao Oswaldo Cruz partnered with TriNetX, joining its global health research network to accelerate clinical research and improve patient outcomes.
This partnership also supports the expansion of the TriNetX network across Brazil and Latin America, leveraging hospital collaborations to foster clinical research. Opportunities in the market include advancements in real-world evidence generation, digital medical education, and global regulatory support. The rise of data-driven decision-making and artificial intelligence tools is further transforming the landscape, offering new efficiencies and innovation in medical affairs outsourcing.
Key Takeaways
- In 2023, the market for medical affairs outsourcing generated a revenue of US$ 1.8 billion, with a CAGR of 7.2%, and is expected to reach US$ 3.6 billion by the year 2033.
- The service segment is divided into medical monitoring, medical information, medical writing & publishing, medical science liaisons, and others, with medical writing & publishing taking the lead in 2023 with a market share of 37.4%.
- Considering industry, the market is divided into pharmaceutical, medical devices, and biopharmaceutical. Among these, pharmaceutical held a significant share of 48.9%.
- North America led the market by securing a market share of 41.2% in 2023.
Service Analysis
The medical writing & publishing segment led in 2023, claiming a market share of 37.4% owing to the increasing demand for accurate and compliant documentation in the healthcare and pharmaceutical sectors. The rising complexity of regulatory requirements and the need for comprehensive clinical study reports, regulatory submissions, and scientific publications are anticipated to fuel the demand for outsourced medical writing services.
Additionally, pharmaceutical companies are likely to seek external expertise for preparing high-quality manuscripts and journal publications to meet the growing need for transparent communication with healthcare professionals and regulatory bodies. The ongoing expansion of clinical trials, particularly in emerging therapeutic areas, is expected to further stimulate the growth of this segment.
Industry Analysis
The pharmaceutical held a significant share of 48.9% due to the rising demand for specialized services in drug development and post-marketing activities. As pharmaceutical companies increasingly focus on reducing operational costs and streamlining their R&D processes, outsourcing medical affairs functions is likely to gain traction.
The growing complexity of drug regulations, coupled with the need for effective communication between stakeholders, is anticipated to drive the demand for outsourced expertise. Moreover, the rise in new drug approvals, particularly in oncology and rare diseases, is expected to further accelerate the adoption of outsourced medical affairs services in the pharmaceutical industry. This trend is also supported by the increasing globalization of clinical trials and the need for multilingual medical affairs teams.
Key Market Segments
By Service
- Medical Monitoring
- Medical Information
- Medical Writing & Publishing
- Medical Science Liaisons
- Others
By Industry
- Pharmaceutical
- Medical Devices
- Biopharmaceutical
Drivers
Growing Demand For Medical Affairs Outsourcing
Growing demand for medical affairs outsourcing is expected to drive market growth as pharmaceutical companies increasingly focus on efficiency and expertise. The need for specialized services, such as regulatory support, scientific communications, and key opinion leader engagement, has risen due to the complexity of modern drug development.
According to an article published by Pharmaceutical Medicine in July 2021, the COVID-19 pandemic significantly altered external stakeholder engagements, positioning medical affairs as a leader in scientific and patient-centric initiatives. Outsourcing allows companies to streamline operations while accessing specialized knowledge. As the global healthcare landscape continues to evolve, this demand for external expertise is anticipated to expand.
Restraints
Rising Risk Of Data Security Breaches
Rising risks of data security and confidentiality breaches are expected to hamper the growth of the medical affairs outsourcing market. Outsourcing sensitive information, such as proprietary research, clinical data, and patient records, increases the risk of cyberattacks and unauthorized access.
These risks create significant concerns for pharmaceutical companies, as a single breach can result in severe financial losses, legal complications, and damage to a company’s reputation. The need for stringent security protocols and data protection measures increases costs, further restraining market expansion. Additionally, companies often hesitate to outsource critical operations due to fears over losing control of confidential information, limiting market growth.
Opportunities
Increasing Growth Of The Biopharmaceutical Industry
Increasing growth of the biopharmaceutical industry presents a substantial opportunity for the medical affairs outsourcing market. The biopharmaceutical sector’s rapid expansion drives demand for specialized services, including regulatory strategy, market access support, and scientific expertise. According to the Pharmaceutical Industry and Global Health Facts and Figures 2021 report, biopharmaceutical research and development spending is 7.3 times higher than that of the aerospace and defense sectors, and significantly outpaces other industries like chemicals and software.
This high level of investment creates opportunities for outsourcing partners to provide critical support, especially as companies seek to accelerate drug development and market entry. As the industry grows, outsourcing is projected to become an essential strategy for managing increasing complexity.
Impact of Macroeconomic / Geopolitical Factors
Macroeconomic instability and geopolitical events significantly affect the medical affairs outsourcing market. Rising inflation and labor costs increase the expenses associated with outsourcing, while economic slowdowns reduce healthcare budgets, causing some companies to limit outsourcing initiatives. Geopolitical tensions, particularly in regions with established outsourcing hubs, disrupt business operations and lead to uncertainties in service delivery.
However, the demand for outsourcing continues to grow as pharmaceutical companies aim to streamline operations and focus on core competencies. Increased government funding for healthcare innovation, particularly in developing countries, provides new opportunities for outsourcing services. As global healthcare demands rise, particularly in response to pandemics and aging populations, the market for medical affairs outsourcing is likely to see sustained growth.
Trends
Rising Mergers and Acquisitions
Rising mergers and acquisitions among key players are projected to drive the medical affairs outsourcing market. In December 2021, RQM+ expanded its regulatory expertise by acquiring AcKnowledge Regulatory Strategies, adding a team of FDA reviewers, scientists, and regulatory specialists. This strategic move strengthened RQM+’s FDA submission capabilities.
Similarly, in February 2021, ICON plc acquired PRA Health Sciences, Inc. in a transaction valued at approximately USD 12 billion, enhancing its medical affairs service offerings. These acquisitions highlight the trend of companies seeking to expand their service portfolios and gain a competitive edge. With increasing consolidation in the industry, more organizations are anticipated to leverage these synergies to improve operational efficiency and expand their client bases.
Regional Analysis
North America is leading the Medical Affairs Outsourcing Market
North America dominated the market with the highest revenue share of 41.2% owing to increasing demand for regulatory compliance and the need for specialized expertise in managing complex medical information. A key factor contributing to this growth was the development of innovative software solutions by companies like Freyr, which gained prominence for its compliance-focused technology.
In November 2021, Freyr was recognized by USA-9 Technology Magazine as one of the “10 Best Technology Solution Providers of 2021,” a distinction that enhanced the company’s reputation in the medical affairs outsourcing sector.
As pharmaceutical and biotech companies faced growing regulatory challenges, outsourcing these functions became a cost-effective solution, allowing businesses to focus on core activities while ensuring compliance with evolving regulations. This trend, along with advancements in digital platforms, has significantly boosted the market’s expansion in the region.
The Asia Pacific region is expected to experience the highest CAGR during the forecast period
Asia Pacific is expected to grow with the fastest CAGR owing to increasing collaborations between global pharmaceutical companies and local institutions. In February 2024, Pfizer partnered with NIPER Ahmedabad to support healthcare startups in India through a one-year accelerator program. This initiative, backed by the Department of Pharmaceuticals and Niti Aayog, aims to foster innovation and transform proof-of-concept ideas into market-ready solutions.
Six selected innovators will receive guidance and resources to accelerate their developments in line with the initiative’s goals. Such partnerships, combined with rising investment in R&D and regulatory services, are anticipated to drive the demand for outsourced medical affairs expertise across the Asia Pacific region. Expanding healthcare infrastructure and government support for innovation are likely to further support market growth in this sector.
Key Regions and Countries
- North America
- US
- Canada
- Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia
- Netherland
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- New Zealand
- Singapore
- Thailand
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
Key Players Analysis
The major players in the medical affairs outsourcing market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Key players in the medical affairs outsourcing market drive growth by offering specialized services that cater to the evolving needs of pharmaceutical and biotechnology companies.
They focus on expanding their service portfolios, including medical writing, regulatory support, and post-market surveillance, to provide comprehensive solutions. Forming strategic partnerships with global healthcare organizations enhances their credibility and reach. Companies also invest in digital platforms and analytics tools to improve service delivery and efficiency. Targeting emerging markets and tailoring services to regional regulatory requirements helps them capture new growth opportunities.
Top Key Players in the Medical Affairs Outsourcing Market
- The Medical Affairs Company
- SGS SA
- RQM+
- Propharma Group
- IQVIA Holdings Inc
- Indegene Inc.
- ICON plc
- Celegence Holdings LLC
- Ashfield Healthcare Communications
Recent Developments
- In March 2024: Celegence Holdings LLC, a life sciences company, invested in Soterius, Inc. through its Series A financing round. Soterius specializes in outsourced services, collaboration technologies, and data assets for drug safety and medical affairs. This partnership is expected to enhance both companies’ market reach and accelerate growth, contributing to the expansion of the medical affairs outsourcing market by combining expertise in drug safety and medical affairs services.
- In October 2021: ProPharma Group acquired Pharmica Consulting, enabling ProPharma to offer enhanced client support throughout the drug lifecycle. This acquisition also allows Pharmica Consulting to expand its services internationally, promoting the growth of the medical affairs outsourcing market by broadening access to expert consulting services globally.
- In December 2021: RQM+, a global MedTech service provider, strengthened its regulatory expertise through the acquisition of AcKnowledge Regulatory Strategies. This acquisition integrates a highly skilled regulatory team into RQM+’s network, enhancing its capabilities in FDA submission experience, which supports the growth of the medical affairs outsourcing market by providing more comprehensive regulatory and quality consulting services.
- In February 2021: ICON plc, a healthcare intelligence and clinical research organization, completed the acquisition of PRA Health Sciences, Inc. for approximately USD 12 billion. This acquisition significantly expanded ICON’s portfolio in medical affairs services, further fueling the growth of the medical affairs outsourcing market by enhancing its capacity to offer comprehensive outsourced solutions.
